244076-70-8

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 56613-80-0 D-2-phenylglycinol 
• 244149-07-3 (1R,2R)-1,2-dicarbomethoxy-3-formyl-cyclopropane 
• 52920-00-0 rac-trans-2,3-dicarbomethoxy-1-formyl-cyclopropane 
• 244076-68-4 (1R,2R)-3-bromo-1,2-dicarbomethoxy-3-(hydroxymethyl)cyclopropane 
• 263169-43-3 (1RS,5R,6R)-1-bromo-4-oxa-bicyclo[3.1.0]hexane-6-carboxylic acid 
• 244076-69-5 (1R,2R)-3-bromo-1,2-dicarbomethoxy-3-formyl-cyclopropane 
• 244076-66-2 (1R,2R)-3-bromo-3-(bromomethyl)cyclopropane-1,2-dicarboxylic acid 

Relevant academic research and scientific papers

(2S,2'R,3'R)-2-(2,3-dicarboxyl-cyclopropyl)-glycine (DCG-1/4) and 3H-DCG-1/4 and to process for the preparation thereof

This invention relates to (2S,2'R,3'R)-2-(2,3-dicarboxyl-cyclopropyl)-glycine of formula wherein R2 is hydrogen or tritium and to a process for the preparation thereof. The described compounds can be used as a pharmacological tool to study the function of

A short and efficient synthesis of (2S,2'R,3'R)-2-(2',3'- dicarboxylcyclopropyl)glycine (DCG-IV)

Feist's acid (5) was used in enantiomerically pure form as starting material for the synthesis of (2S,2'R,3'R)-2-(2',3'-dicarboxylcyclopropyl)- glycine (DCG-IV) (2). This conformationally restricted analog of L-glutamic acid (L-Glu) 1 is a potent group II mGlu receptor agonist.